The MONARCH-E study enrolled HR + /HER2- breast cancer patients with ≥ 4 positive lymph nodes or 1–3 positive nodes accompanied by high-risk features, such as histological grade 3, tumor size > 5 cm, or Ki-67 > 20%. Here, ERBB2 is linked to breast carcinoma.